BioMarin Closes Amicus Deal As FOLD Delists And Indices Adjust
BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, previously listed as NasdaqGM:FOLD. Following the transaction, Amicus has been delisted from the Nasdaq and removed from major indices including the S&P and Russell families. The deal ends Amicus's status as an independent public company and sets up integration of its rare disease portfolio into BioMarin. For investors who followed Amicus Therapeutics at a share price of $14.49 and a value score of 3, the...
BioMarin Pharmaceutical has completed its acquisition of Amicus Therapeutics, previously listed as NasdaqGM:FOLD.
Following the transaction, Amicus has been delisted from the Nasdaq and removed from major indices including the S&P and Russell families.
The deal ends Amicus's status as an independent public company and sets up integration of its rare disease portfolio into BioMarin.
For investors who followed Amicus Therapeutics at a share price of $14.49 and a value score of 3, the...
What's Your Reaction?
:max_bytes(150000):strip_icc()/GettyImages-2187410260-5afe56694791404f99c253dd8d5abe6a.jpg?#)
